Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eisai Limited
This is an observational non-interventional registry. All patients will sign and date an Informed Consent Form (ICF) before enrollment (Baseline Visit). Normal clinical practice will be followed. Patients will continue to follow their usual schedule of clinic visits as determined by their physician, during which information and patient-completed questionnaires will be collected (at scheduled intervals timed to coincide with pump refill).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients will be eligible to enroll onto the registry if they have given informed consent and meet the following criteria:
Patient's physician has deemed that the initiation/switch of intrathecal analgesia appropriate, or patient is presently utilizing ziconotide (Prialt)
Patient has a diagnosis of severe, chronic pain for which intrathecal infusion is indicated
Patient is at least 18 years of age at time of study entry
All patients starting ziconotide (Prialt) should comply with the indications and warnings in the current approved version of the Summary of Product Characteristics (SmPC).
You may not be if
Patients who meet any of the following criteria will not be eligible to enroll in the registry:
Patient is a pregnant or lactating female
Patient is receiving intrathecal chemotherapy
Clareo Health | Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.
